ELIZABETH LITKOWSKI

Ms. ELIZABETH LITKOWSKI


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
ELELIZABETH LITKOWSKI
ELIZABETH LITKOWSKI
MLMark W. Logue
Mark W. Logue
RZRui Zhang
Rui Zhang
BCBrian R. Charest
Brian R. Charest
ELEthan M. Lange
Ethan M. Lange
T(The Va Million Veteran Program (Mvp)
The Va Million Veteran Program (Mvp)

2 June 2022 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
SRSridharan Raghavan
Sridharan Raghavan
JHJie Huang
Jie Huang
CTCatherine Tcheandjieu
Catherine Tcheandjieu
JHJennifer E. Huffman
Jennifer E. Huffman
ELELIZABETH LITKOWSKI
ELIZABETH LITKOWSKI
TAThemistocles L. Assimes
Themistocles L. Assimes
Background: Height has been associated with many clinical traits but whether such associations are causal versus secondary to confounding remains unclear in many cases. To systematically examine this question, we performed a Mendelian Randomization-Phenome-wide association study (MR-PheWAS) using clinical and genetic data from a national healthcare system biobank. Methods and findings: Analyses were performed using data from the US Veterans Affairs (VA) Million Veteran Program in non-Hispanic White (EA, n = 222,300) and non-Hispanic Black (AA, n = 58,151) adults in the US. We estimated height genetic risk based on 3290 height-associated variants from a recent European-ancestry genome-wide meta-analysis. We compared associations of measured and genetically-predicted height with phenome-wide traits derived from the VA electronic health record, adjusting for age, sex, and genetic principal components. We found 345 clinical traits associated with measured height in EA and an additional 17 in AA. Of these, 127 were associated with genetically-predicted height at phenome-wide significance in EA and 2 in AA. These associations were largely independent from body mass index. We confirmed several previously described MR associations between height and cardiovascular disease traits such as hypertension, hyperlipidemia, coronary heart disease (CHD), and atrial fibrillation, and further uncovered MR associations with venous circulatory disorders and peripheral neuropathy in the presence and absence of diabetes. As a number of traits associated with genetically-predicted height frequently co-occur with CHD, we evaluated effect modification by CHD status of genetically-predicted height associations with risk factors for and complications of CHD. We found modification of effects of MR associations by CHD status for atrial fibrillation/flutter but not for hypertension, hyperlipidemia, or venous circulatory disorders. Conclusions: We conclude that height may be an unrecognized but biologically plausible risk factor for several common conditions in adults. However, more studies are needed to reliably exclude horizontal pleiotropy as a driving force behind at least some of the MR associations observed in this study.

30 August 2022 in Diabetes Care
Verified
Journal Article
Open access
PDF file
ELELIZABETH LITKOWSKI
ELIZABETH LITKOWSKI
MLMark W. Logue
Mark W. Logue
RZRui Zhang
Rui Zhang
BCBrian R. Charest
Brian R. Charest
ELEthan M. Lange
Ethan M. Lange
SRSridharan Raghavan
Sridharan Raghavan
OBJECTIVE: Diabetes and dementia are diseases of high health care burden worldwide, and studies have shown that diabetes is associated with an increased relative risk of dementia. We set out to examine whether type 2 diabetes–associated genetic variants were associated with dementia and whether they differed by race/ethnicity or clinical dementia diagnosis. RESEARCH DESIGN AND METHODS: We evaluated associations of two type 2 diabetes genetic risk scores (GRS and GRS-nonAPOE: a score without rs429358, a variant associated with Alzheimer disease [AD]) with three classifications of clinical dementia diagnoses in the Million Veteran Program (MVP): all-cause dementia, vascular dementia (VaD), and AD. We conducted our analysis stratified by European (EUR), African (AFR), and Hispanic (HIS) races/ethnicities. RESULTS: In EUR, we found associations of the GRS with all-cause dementia (odds ratio [OR] 1.06, P = 1.60e−07) and clinically diagnosed VaD (OR 1.12, P = 5.2e−05) but not with clinically diagnosed AD (OR 1.02, P = 0.43). The GRS was not associated with any dementia outcome in AFR or HIS. When testing with GRS-nonAPOE, we found that effect size estimates in EUR increased and P values decreased for all-cause dementia (OR 1.08, P = 2.6e−12), for VaD (OR 1.14, P = 7.2e−07), and for AD (OR 1.06, P = 0.018). For AFR, the association of GRS-nonAPOE and clinically diagnosed VaD (OR 1.15, P = 0.016) was statistically significant. There were no significant findings for HIS. CONCLUSIONS: We found evidence suggesting shared genetic pathogenesis of diabetes with all-cause dementia and clinically diagnosed VaD.

16 August 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
EHEmily B. Hill
Emily B. Hill
IKIain Konigsberg
Iain Konigsberg
DIDiana Ir
Diana Ir
DFDaniel Frank
Daniel Frank
PJPurevsuren Jambal
Purevsuren Jambal
SBSarah J. Borengasser
Sarah J. Borengasser
Obesity has been linked to the gut microbiome, epigenome, and diet, yet these factors have not been studied together during obesity treatment. Our objective was to evaluate associations among gut microbiota (MB), DNA methylation (DNAme), and diet prior to and during a behavioral weight loss intervention. Adults (n = 47, age 40.9 ± 9.7 years, body mass index (BMI) 33.5 ± 4.5 kg/m2, 77% female) with data collected at baseline (BL) and 3 months (3 m) were included. Fecal MB was assessed via 16S sequencing and whole blood DNAme via the Infinium EPIC array. Food group and nutrient intakes and Healthy Eating Index (HEI) scores were calculated from 7-day diet records. Linear models were used to test for the effect of taxa relative abundance on DNAme and diet cross-sectionally at each time point, adjusting for confounders and a false discovery rate of 5%. Mean weight loss was 6.2 ± 3.9% at 3 m. At BL, one MB taxon, Ruminiclostridium, was associated with DNAme of the genes COL20A1 (r = 0.651, p = 0.029), COL18A1 (r = 0.578, p = 0.044), and NT5E (r = 0.365, p = 0.043). At 3 m, there were 14 unique MB:DNAme associations, such as Akkermansia with DNAme of GUSB (r = −0.585, p = 0.003), CRYL1 (r = −0.419, p = 0.007), C9 (r = −0.439, p = 0.019), and GMDS (r = −0.559, p = 0.046). Among taxa associated with DNAme, no significant relationships were seen with dietary intakes of relevant nutrients, food groups, or HEI scores. Our findings indicate that microbes linked to mucin degradation, short-chain fatty acid production, and body weight are associated with DNAme of phenotypically relevant genes. These relationships offer an initial understanding of the possible routes by which alterations in gut MB may influence metabolism during weight loss.

15 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMagdalena Sevilla-González
Magdalena Sevilla-González
KSKirk Smith
Kirk Smith
NWNingyuan Wang
Ningyuan Wang
AJAubrey E. Jensen
Aubrey E. Jensen
ELELIZABETH LITKOWSKI
ELIZABETH LITKOWSKI
AMAlisa K. Manning
Alisa K. Manning
Elevated fasting insulin levels (FI), indicative of altered insulin secretion and sensitivity, may precede type 2 diabetes (T2D) and cardiovascular disease onset. In this study, we group FI-associated genetic variants based on their genetic and phenotypic similarities and identify seven clusters with distinct mechanisms contributing to elevated FI levels. Clusters fall into two types: “non-diabetogenic hyperinsulinemia,” where clusters are not associated with increased T2D risk, and “diabetogenic hyperinsulinemia,” where T2D associations are driven by body fat distribution, liver function, circulating lipids, or inflammation. In over 1.1 million multi-ancestry individuals, we demonstrated that diabetogenic hyperinsulinemia cluster-specific polygenic scores exhibit varying risks for cardiovascular conditions, including coronary artery disease, myocardial infarction (MI), and stroke. Notably, the visceral adiposity cluster shows sex-specific effects for MI risk in males without T2D. This study underscores processes that decouple elevated FI levels from T2D and cardiovascular risk, offering new avenues for investigating process-specific pathways of disease.

18 December 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
KHKylie K Harrall
Kylie K Harrall
DGDeborah H Glueck
Deborah H Glueck
LLLeslie A Lange
Leslie A Lange
ELELIZABETH LITKOWSKI
ELIZABETH LITKOWSKI
LVLauren A Vanderlinden
Lauren A Vanderlinden
DDDana Dabelea
Dana Dabelea
Context: This is the first study to examine the association between variants of the glucagon-like-peptide-1 receptor gene (GLP-1R) and metabolic characteristics among youth. Objective: We explored separate associations of 3 GLP-1R polymorphisms (rs10305420, rs6923761, and rs1042044) with body mass index (BMI) trajectories and markers of glucose-insulin homeostasis. Methods: Mixed models examined associations between GLP-1R polymorphisms and trajectories of BMI. Linear models examined associations of GLP-1R polymorphisms with glucose and insulin concentrations across oral glucose tolerance test (OGTT), insulin sensitivity (HOMA2-IR), insulin secretion (insulinogenic index and HOMA2-%B), and β-cell function (oral disposition index). Results: Rs10305420 and rs6923761, but not rs1042044, were associated with growth and metabolic characteristics in early life. Rs6923761 genotype GG was associated with faster BMI growth velocity, when compared to carriers of the minor allele (difference in velocity [95% CI]: 0.16/year [0.07-0.24] at age 10), which led to significantly higher average BMI by age 16 (average difference [95% CI]: 1.29 [0.22-2.37]). Rs10305420 CC and rs6923761 GG genotypes had higher HOMA2-IR (β [95% CI]: 1.19% [1.06-1.32] and 1.13% [1.01-1.26], respectively) compared to minor allele carriers. Rs10305420 CC had higher HOMA2-%B (β [95% CI]: 1.09% [1.01-1.17]), and higher stimulated insulin secretion at 30 minutes (β [95% CI]: 27.62 μIU/mL [3.00-25.24]) and 120 minutes (β [95% CI]: 18.94 μIU/mL [1.04-36.84]), when compared to carriers of the minor allele. Conclusion: GLP-1R polymorphisms are associated with faster BMI growth across development, and lower estimated insulin sensitivity and higher compensatory insulin secretion during adolescence. GLP-1R polymorphisms should be considered in future pediatric studies of genetic susceptibility for obesity and diabetes.